This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that causes your bone marrow to make too many of a type of white blood cells called lymphocytes. Unlike other types of leukemia, it’s a ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Until recently, a chronic lymphocytic leukemia (CLL) diagnosis came with limited options and a lot of uncertainty. Today, long-term results show how much treatment has changed — and what patients and ...

Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...